A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With Mild COVID-19
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 274
- 试验地点
- 11
- 主要终点
- Total incidence frequency of progression to moderate COVID-19 illness or worse throughout the study (by Day 31)
研究概览
简要总结
The innovative drug XC221 100 mg tablet is designed for the treatment of COVID-19 (SARS-CoV-2 infection). A multicenter, adaptive, randomized, double-blind, placebo-controlled Phase III clinical study is aimed to assess the efficacy and safety of XC221 100 mg tablet, in mild COVID-19 patients during a 14-days treatment.
The primary objective of the study is to demonstrate the efficacy of XC221 100 mg tablet (200 mg daily dose) in achieving clinical improvement of mild COVID-19 symptoms.
The secondary objective of the study is to evaluate the safety of XC221 100 mg tablet (200 mg daily dose) in mild COVID-19 patients.
详细描述
8 Russian centers will participate in this study. The trail will consist of three periods: screening (duration not more than 1 day, it may coincide with the randomization visit and beginning of drug administration), treatment period (14 full days) and follow-up period (15 ± 1 days after completion of treatment with XC221 / Placebo). The duration of participation in the study for each patient will be no more than 32 days.
274 eligible patients with confirmed COVID-19 will be randomized into two groups (Group A and Group B) in a 1:1 ratio: Group A - XC221 200 mg daily (137 patients); Group В - Placebo (137 patients).
During the treatment period (14 full days), 1 tablet of XC221 / Placebo will be administered 2 times a day in addition to the standard of care (SoC) for COVID-19 according to The Temporary guidelines for the prevention, diagnosis and treatment of SARS-CoV-2 infection of the Ministry of Health of the Russian Federation (the MoH Temporary Guidelines). The follow-up period will last for 15 ± 1 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
Tablets identical in terms of composition, appearance and labeling to XC221 tablets, but without active substance will be used as Placebo.
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form.
- •Patients of both sexes aged 18 to 75 years inclusive.
- •Diagnosed COVID-19 based on positive laboratory tests confirming the SARS-CoV-2 presence, performed no earlier than 3 days before screening. It is allowed to determine the SARS-CoV-2 by the PCR or by another method according to the MoH Temporary Guidelines.
- •Patients having a total score ≥ 5 according to the COVID-19 Major Symptom Rating Scale.
- •Patients with mild COVID-19, as defined in The MoH Temporary Guidelines. Presence of at least two criteria: SpO2 ≥ 95% (required criterion), 37.5°С ≤ t ˂ 38°С, or respiratory rate (RR) ≤ 22 / min. Absence of moderate/severe progression criteria.
- •Disease duration is no more than 3 full days since the onset of one or more of symptoms below before the first dose of the drug administration:
- •body temperature increase;
- •dry cough or cough with little phlegm;
- •dyspnoea;
- •feeling of congestion in the chest;
- •reduced sense of smell and / or taste.
- •For women only: negative pregnancy test result. Pregnancy testing is not required for women of not childbearing potential (WONCBP): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". The presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition.
- •Consent to use reliable method of contraception throughout the study period.
- •Patients who are able to understand and comply with treatment and procedures during the study.
排除标准
- •Known or suspected hypersensitivity to the active substance or to excipients of the drug XC221 or placebo
- •Known or suspected hypersensitivity to standard therapy drugs specified in The MoH Temporary Guidelines.
- •Body temperature ˂37.5°С.
- •Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
- •Presence or suspicion of oncological diseases by the day of criteria assessment or in medical history (within the last 2 years).
- •Presence of autoimmune diseases by the day of criteria assessment or in medical history.
- •Lactation period.
- •Presence of serious lung diseases, including, but not limited to the following diseases: moderate and severe bronchial asthma, severe and extremely severe COPD, interstitial lung disease, pulmonary hypertension, pulmonary fibrosis, surgical interventions on the lungs, tuberculosis (including suspicion of tuberculosis based on the results of CT examination at screening).
- •Patients with type 1 diabetes mellitus and / or decompensated type 2 diabetes mellitus.
- •Heart failure, NYHA functional class III - IV.
- •Chronic liver failure stage II (decompensated) and higher.
- •The need of replacement renal therapy at enrollment.
- •Organ transplantation in medical history.
- •Medical history of epilepsy or the need for anticonvulsant therapy.
- •Major depressive disorder, anxiety, other mental disorders requiring medical correction.
- •Acute cerebrovascular accident, stroke or transient ischemic attack within 90 days before screening.
- •Use of any antiviral and / or immunomodulatory drugs after the manifestation of COVID-
- •Any immunosuppressive therapy (including tocilizumab / sarilumab) within 90 days prior to randomization, or the need of immunosuppressive therapy at the time of randomization.
- •Use of anti-COVID-19 plasma within 14 days prior to the screening visit.
- •Use of systemic glucocorticosteroids within 90 days prior to randomization, or the need of systemic glucocorticosteroids at the time of randomization.
- •Use of vaccines against viral infections within 90 days prior to randomization.
- •Patients receiving other experimental drugs, drugs not approved in the Russian Federation, or participating in other clinical trials within 30 days before screening.
- •Patients abusing alcohol or psychotropic drugs and other drugs by the day of criteria assessment or during the last year.
- •Patients with other serious, unstable, or clinically significant medical or psychological conditions that, in the opinion of the investigator, may preclude the patient's participation in the study.
研究组 & 干预措施
XC221
XC221 100 mg orally. 1 tablet of XC221 100 mg 2 times a day during 14 full days of treatment period
干预措施: XC221 (Drug)
Placebo
Placebo orally. 1 tablet of Placebo 2 times a day during 14 full days of treatment period
干预措施: Placebo (Drug)
结局指标
主要结局
Total incidence frequency of progression to moderate COVID-19 illness or worse throughout the study (by Day 31)
时间窗: Day 1 - Day 31
Moderate illness parameters: * Body temperature \> 37.5°C; * RR \> 22 / min; * Dyspnea during exercise; * Changes in CT (X-Ray) typical of viral disease (the volume of affected area is minimal or medium, CT 1-2); * SpO2 ˂ 95%; * Serum CRP \> 10 mg/l For the symptoms (body temperature, RR, dyspnea during exercise, SpO2, progression to moderate COVID-19 or worse), the presence of moderate progression criteria as shown by the second of two consecutive measurements.
The median time to a stable decrease in the total score on the COVID-19 Major Symptom Rating Scale to ≤ 1. A stable total score decrease is the presence of 1 point or less as shown by the second of two consecutive measurements
时间窗: Day 1 - Day 31
The COVID-19 Major Symptom Rating Scale will be used to assess the individuals' subjective ratings the severity of 9 symptoms of COVID-19. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 27 points) is a sum of points for each symptom.
次要结局
- Mean change from baseline in SpO2 by Day 2-31(Day 1 - Day 31)
- Patient rate with RR > 22/min by Days 3, 6, 9, 12 and 15(Day 1 - Day 15)
- Patient rate with SpO2 ˂ 95% by Day 2-31(Day 1 - Day 31)
- Patient rate with worsening for one or more grades of the WHO Scale by Day 2-31(Day 1 - Day 31)
- Patient rate with SpO2 ≤ 93% by Day 2-31(Day 1 - Day 31)
- Patient rate with improvement for one or more grades of the WHO Scale by Day 2-31(Day 1 - Day 31)
- Mean WHO Scale grade changes from baseline by Day 2-31(Day 1 - Day 31)
- Patient rate with RR > 30/min by Days 3, 6, 9, 12 and 15(Day 1 - Day 15)
- Patient rate with RR ≤ 20/min by Days 3, 6, 9, 12 and 15(Day 1 - Day 15)
- Mean change from baseline in RR by Days 3, 6, 9, 12 and 15(Day 1 - Day 15)
- Patient rate with a body temperature ≤ 37.0°С by Day 2-31(Day 1 - Day 31)
- Patient rate with a body temperature ≤ 37.5°С by Day 2-31(Day 1 - Day 31)
- Patient rate with a body temperature ≥ 38.5°С by Day 2-31(Day 1 - Day 31)
- Mean change from baseline in body temperature by Day 2-31(Day 1 - Day 31)
- Patient rate with a score ≤ 1 according to the Daytime and Nighttime Cough Scale by Day 2-31(Day 1 - Day 31)
- Mean score change from baseline in the Daytime and Nighttime Cough Scale by Day 2-31(Day 1 - Day 31)
- Patient rate with decrease for one or more grades for each symptom according to the COVID-19 Major Symptom Rating Scale by Day 2-31(Day 1 - Day 31)
- Patient rate with clinical improvement (1 point or less) for each symptom according to the COVID-19 Major Symptom Rating Scale(Day 1 - Day 31)
- Time till clinical improvement (1 point or less) for each symptom according to the COVID-19 Major Symptom Rating Scale(Day 1 - Day 31)
- Patient rate with a grade ≤ 1 for each symptom according to the COVID-19 Major Symptom Rating Scale by Day 2-31(Day 1 - Day 31)
- Average time to reach ≤ 1 score according to the Dyspnea Visual Analogue Scale(Day 1 - Day 31)
- Average time to reach ≤ 1 score according to the Daytime and Nighttime Cough.(Day 1 - Day 31)
- Average time to reach ≤ 1 score for each symptom according to the COVID-19 Major Symptom Rating Scale(Day 1 - Day 31)
- Mean score change from baseline for each symptom according to the COVID-19 Major Symptom Rating Scale by Day 2-31(Day 1 - Day 31)
- Patient rate with a grade ≤ 1 according to the Dyspnea Visual Analogue Scale by Day 2-31(Day 1 - Day 31)
- Patient rate with a negative SARS-CoV-2 test result by Day 3, 9, 15, also by Day 7 and Day 15 after the end of drug administration (in the case of a positive previous test result)(Day 1 - Day 31)
- Time till elimination SARS-CoV-2(Day 1 - Day 31)
- Mean CRP concentration change from baseline by Day 15(Day 1 - Day 15)
- Mean score change from baseline according to the Dyspnea Visual Analogue Scale by Day 2-31(Day 1 - Day 31)